Showing results (161-170 of 207) with videos related to

Sort By:
Pageof 21
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 11, 2009
The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4Amitha Domalpally, Barbara A Blodi, Ingrid U Scott, et al.
The Journal of School Health|March 1, 1995
High school students' perceptions of nonconsensual sexual activityS K Telljohann, J H Price, J Summers, et al.
Ophthalmology|April 7, 2009
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion typeIngrid U Scott, Barbara A Blodi, Michael S Ip, et al.
Ophthalmology|October 8, 2010
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10Ingrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|February 25, 2018
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical TrialIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
Ophthalmology|January 27, 2009
SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusionIngrid U Scott, Paul C VanVeldhuisen, Neal L Oden, et al.
JAMA Ophthalmology|December 28, 2018
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 StudyMichael S Ip, Neal L Oden, Ingrid U Scott, et al.
JAMA Ophthalmology|October 28, 2021
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical TrialAhmad A Aref, Ingrid U Scott, Paul C VanVeldhuisen, et al.
Ophthalmology|November 20, 2016
SCORE2 Report 2: Study Design and Baseline CharacteristicsIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
JAMA Ophthalmology|May 11, 2023
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialSteven M Kymes, Neal L Oden, Paul C VanVeldhuisen, et al.
Pageof 21